The BioData Innovation Centre (BIC) was built and opened in 2016 to provide a home for genomics and biodata companies. The building provides flexible space for innovative businesses as well as individuals that complement the unique research and innovation of the Campus Institutes.
Leasable office spaces are within a range of dry lab units at sizes to suit individuals and early start-ups, through to larger and more established businesses. Unit sizes range from 19m2 to 330m2.
Businesses located in the BIC benefit from the array of existing amenities and services on the Campus, including world-class information technology and bioinformatics infrastructure and services. There is parking and coach transport across the local area; catering, sports facilities and social activities; conferencing, exhibition and meeting room space; on-Campus accommodation for visitors and extensive award-winning grounds.
Join a world-class hub for genomics and biodata and engage with our diverse and exceptional scientific community. Full details of how tenancy at the BIC works, are available on request.
Hot-desking at the BioData Innovation Centre
Individual entrepreneurs and innovators who are applying a genomics or a bioinformatics focus to their work are invited to join the vibrant community of companies on site and to enjoy many of the benefits of Campus life.Find out more
3,000 sq m
of space in the building over 2 floors
1,400 sq m
Leasable office space
200 sq m
Cafe with a capacity for 80 people
free underground parking spaces + bike racks
The Atos Life Sciences Center of Excellence brings leading-edge technologies closer to research projects with the goal of discovering fresh, innovative solutions that will have a positive impact in society.
Broken String biosciences
Broken String Biosciences is a genomics company with the goal of advancing therapeutic discovery and development by assessing the stability of the genome.
Congenica was founded in 2012 by Dr Tom Weaver, Dr Richard Durbin, Dr Matthew Hurles, Dr Nick Lench and Professor Phil Beales as a spin-out company from the Sanger Institute.
A trusted navigational tool for precision oncology. Cancer genomics is growing exponentially. Our expert curation process captures, analyses, and displays the wealth of data in world-renowned databases.
Eagle Genomics’ award-winning AI augmented knowledge discovery platform, the e[automateddatascientist], is revolutionising how scientists conduct life sciences research putting data science at the fingertips of biologists drastically reducing time and cost of research.
Genomics England was set up in 2013 as a company wholly owned by the Department of Health. Their task is to deliver the 100,000 Genomes Project, a flagship project that will sequence 100,000 whole genomes from NHS patients with rare disease and their families, and common cancers.
Empowering data collaboration in genomics for the benefit of human health. GenXT implements Confidential Computing technologies for secure and privacy-preserving multi-party analytics of genomic and medical data. Confidential Computing is the protection of data-in-use by performing computation in a hardware-based Trusted Execution Environment.
Founded in 1998, Illumina has grown to serve research and clinical customers in a broad range of markets including oncology, reproductive health, agriculture, complex disease and microbiology. Illumina is a global company with its headquarters in San Diego, and offices in Europe, Middle East, and Africa.
Mosaic is a spin out of the Wellcome Sanger Institute. It is a cancer drug discovery company disrupting the traditional way of treating cancers based upon their tissue of origin – a paradigm that fails most patients. Mosaic's unique approach is rooted in the science of the cancer itself. Changes in the DNA of a cancer cell enable it to grow unchecked, but at the cost of creating weaknesses which can be targeted.
SciBite was founded in 2013, in response to a gap in robust, industry-centric text analytics solutions. Since then, the company has rapidly grown, winning a number of industry awards (most notably the Queen's Awards for Enterprise twice in a row) and expanding its operations to the US and Japan over the last two years.
The Wellcome Genome Campus is second-to-none in terms of the facilities it offers to Eagle, as well as the thriving intellectual and social community. Being co-located with centres of excellence like EMBL-EBI and the Wellcome Sanger Institute is a real advantage for us.
Glenn Proctor, Former VP of Software Development, Eagle Genomics